Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Delaying surgery for patients with a previous SARS-CoV-2 infection

    Research output: Contribution to journalLetterpeer-review

  2. Perioperative care guidelines: conflicts and controversies

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Differential recurrence after laparoscopic incisional hernia repair: importance of a nationwide registry-based mesh surveillance

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Response to: Meticulous surgical technique cannot be replaced by cholangiography

    Research output: Contribution to journalLetterpeer-review

  1. Road and railway noise and risk for breast cancer: A nationwide study covering Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Ductal carcinoma in situ (DCIS) in the breast that is diagnosed by biopsy implies a risk of upstaging to invasive carcinoma (IC) on final pathology. These patients require a sentinel lymph node biopsy (SLNB) for axillary staging. A two-stage procedure is not always feasible and precise selection of patients who should be offered SLNB is crucial. The aims were: to determine the rate of upstaging, and use of redundant and required SLNB in women with a preoperative diagnosis of DCIS; and to identify patient and tumour characteristics that increase the risk of upstaging.

METHODS: Patients with DCIS treated between 2008 and 2016 were identified using Orbit operation planning system software, and those suitable for the study were selected based on review of the medical records. Upstaging rates and proportions of redundant and required SLNBs were calculated. Associations between clinicopathological characteristics and upstaging were analysed using univariable and multivariable logistic regression analyses.

RESULTS: Of 1368 patients initially identified, 975 women with a preoperative diagnosis of DCIS were included in the study. Tumours in 246 of these patients (25·2 per cent) were upstaged to IC. Redundant SLNB was performed in 392 of 975 women (40·2 per cent). Forty-four patients (4·5 per cent) with a final diagnosis of IC were not offered SLNB and thus potentially undertreated. In adjusted analysis, DCIS size, palpability and mass formation identified by breast imaging were associated with increased risk of upstaging. The Van Nuys classification was not associated with upstaging.

CONCLUSION: Most patients with IC on final pathology underwent SLNB, but a considerable number of patients with DCIS had a redundant SLNB. Lesion size, palpability and mass formation, but not Van Nuys classification group, are suggested risk factors for upstaging.

Original languageEnglish
JournalThe British journal of surgery
Volume107
Issue number1
Pages (from-to)96-102
Number of pages7
ISSN0007-1323
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Breast Neoplasms/pathology, Carcinoma, Ductal, Breast/pathology, Carcinoma, Intraductal, Noninfiltrating/pathology, Female, Humans, Mastectomy/statistics & numerical data, Middle Aged, Neoplasm Staging, Preoperative Care, Risk Factors, Sentinel Lymph Node Biopsy, Tumor Burden

ID: 61894939